Use of glutamine synthetase for treating hyperammonemia
US12359184B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | May 24, 2018 |
| Grant date | Jul 15, 2025 |
| Priority date | — |
| Expiry date | Jan 6, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K19/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the use of glutamine synthetase as a protein therapy (such as enzyme replacement protein therapy) for the treatment of hyperammonemia. In particular the invention relates to the systemic administration of glutamine synthetase. The glutamine synthetase may be provided in conjugated or fusion form, to increase its half-life in the circulation. Also provided is a pharmaceutical composition comprising glutamine synthetase. The invention also relates to the uses, methods and compositions involving a combination of the glutamine synthetase protein and an ammonia lowering agent, such as a nitrogen scavenger.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.